Cardiff Oncology Inc (NASDAQ: CRDF) kicked off on Monday, down -3.88% from the previous trading day, before settling in for the closing price of $3.61. Over the past 52 weeks, CRDF has traded in a range of $1.44-$6.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 20.41% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -6.21%. With a float of $61.33 million, this company’s outstanding shares have now reached $66.52 million.
In an organization with 32 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 55.01%, operating margin of -6735.99%, and the pretax margin is -6239.04%.
Cardiff Oncology Inc (CRDF) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 7.80%, while institutional ownership is 27.28%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.21% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Take a look at Cardiff Oncology Inc’s (CRDF) current performance indicators. Last quarter, stock had a quick ratio of 4.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 334.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Let’s dig in a bit further. During the last 5-days, its volume was 1.29 million. That was inferior than the volume of 1.37 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 4.88%. Additionally, its Average True Range was 0.43.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 38.88%, which indicates a significant increase from 4.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.12% in the past 14 days, which was lower than the 127.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.43, while its 200-day Moving Average is $3.14. However, in the short run, Cardiff Oncology Inc’s stock first resistance to watch stands at $3.60. Second resistance stands at $3.74. The third major resistance level sits at $3.83. If the price goes on to break the first support level at $3.37, it is likely to go to the next support level at $3.28. Assuming the price breaks the second support level, the third support level stands at $3.14.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
The company with the Market Capitalisation of 230.82 million has total of 51,134K Shares Outstanding. Its annual sales at the moment are 490 K in contrast with the sum of -41,440 K annual income. Company’s last quarter sales were recorded 170 K and last quarter income was -11,860 K.
